Table 5.

Stratification analysis between FTO genotypes and glioma risk

Variables	rs8047395 (cases/controls)		AOR (95% CI)a	pa	Protective genotypesb (cases/controls)		AOR (95% CI)a	pa
	AA	AG/GG			0–2	3–4
Age, months
<60	39/41	46/78	0.62 (0.35–1.09)	0.098	38/41	47/78	0.65 (0.37–1.15)	0.138
≥60	36/34	50/75	0.64 (0.35–1.15)	0.133	35/33	51/76	0.64 (0.35–1.16)	0.139
Gender
Females	36/30	45/63	0.61 (0.32–1.13)	0.116	35/30	46/63	0.64 (0.34–1.19)	0.159
Males	39/45	51/90	0.65 (0.37–1.12)	0.120	38/44	52/91	0.65 (0.37–1.13)	0.128
Subtypes
Astrocytic tumors	55/75	70/153	0.62 (0.39–0.98)c	0.039c	53/74	72/154	0.64 (0.41–1.02)	0.060
Ependymoma	12/75	13/153	0.53 (0.23–1.23)	0.141	12/74	13/154	0.53 (0.23–1.22)	0.137
Neuronal and mixed	6/75	8/153	0.66 (0.22–1.99)	0.459	6/74	8/154	0.65 (0.22–1.86)	0.444
Embryonal tumors	2/75	5/153	1.31 (0.22–7.85)	0.767	2/74	5/154	1.23 (0.21–7.26)	0.821
Tumor grades
I	48/75	55/153	0.58 (0.36–0.93)c	0.025c	47/74	56/154	0.58 (0.36–0.95)c	0.029c
II	11/75	17/153	0.76 (0.34–1.70)	0.504	11/74	17/154	0.74 (0.33–1.67)	0.473
III	8/75	7/153	0.44 (0.15–1.26)	0.124	8/74	7/154	0.43 (0.15–1.25)	0.120
IV	8/75	17/153	1.07 (0.42–2.73)	0.892	7/74	18/154	1.27 (0.48–3.34)	0.635
I+II	59/75	72/153	0.60 (0.39–0.94)c	0.026c	58/74	73/154	0.61 (0.39–0.95)c	0.028c
III+IV	16/75	24/153	0.72 (0.36–1.45)	0.355	15/74	25/154	0.78 (0.38–1.58)	0.489

AOR, adjusted odds ratio; CI, confidence interval.

^aAdjusted for age and gender, omitting the corresponding stratify factor.

^bProtective genotypes were carriers with rs1477196 GA/AA, rs9939609 TT/TA, rs7206790 CC/CG, and rs8047395 GT/TT genotypes.

^cSignificant results.